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INHALED NITRIC OXIDE 
FALLS TO CONFER THE 
PULMONARY PROTECTION 
PROVIDED BY DISTAL 
STIMULATION OF THE 
NITRIC OXIDE PATHWAY 
AT THE LEVEL OF 
CYCLIC GUANOSINE 
MONOPHOSPHATE 
It has been suggested that inhaled nitric oxide gas may be beneficial after 
lung transplantation, because ndogenous levels of pulmonary nitric oxide 
decline rapidly after reperfusion. However theoretical concerns remain 
about the formation of highly toxic oxidants during the quenching of nitric 
oxide by superoxide. To determine whether distal stimulation of the nitric 
oxide-cyclic guanosine monophosphate pathway at the level of cyclic guan- 
osine monophosphate might confer the beneficial vascular effects of nitric 
oxide without its potential toxicities, we studied an orthotopic rat left lung 
transplant model. In this model, hemodynamic and survival measurements 
can be obtained independent of the native right lung. Lungs were preserved 
for 6 hours at 4°C in Euro-Collins solution alone (control, n = 6) or 
supplemented with the cyclic guanosine monophosphate analog, 8-(4- 
chlorophenylthio)-guanosine-3',5'lCyclic guanosine monophosphate (cGMP, 
n = 4). In additional experiments in which lungs were preserved with 
Euro-Collins solution alone, inhaled nitric oxide was administered uring 
reperfusion (NO, n = 12). Thirty minutes after transplantation and ligation 
of the native right pulmonary artery, pulmonary vascular resistance, 
arterial oxygenation, graft neutrophil infiltration (myeloperoxidase activi- 
ty), and recipient survival were evaluated. Cyclic guanosine monophos- 
phate decreased pulmonary vascular esistance (1.1 -+ 0.2 vs 12.1 _+ 6.3 mm 
Hg/ml/min, p < 0.05), improved oxygen tension (369 - 56 vs 82.8 -+ 48 mm 
Hg, p < 0.05), reduced myeloperoxidase activity (1.7 - 0.3 vs 3.1 -+ 0.9 
AAbs 460 nm/min, p < 0.05), and improved recipient survival (100% vs 0%, 
p < 0.005) compared with Euro-Collins solution alone (control group). 
Animals receiving inhaled nitric oxide during reperfusion did not differ from 
control animals with respect o any of these parameters. These data suggest 
that distal stimulation of the nitric oxide-cyclic guanosine monophosphate 
pathway at the level of cyclic guanosine monophosphate has a protective ffect 
that is not seen with inhaled nitric oxide in the immediate pulmonary 
reperfusion period. (J THORAC CARDIOVASC SURG 1995;110:1434-41) 
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characterized by elevated pulmonary vascular esis- 
tance (PVR), poor gas exchange, and neutrophil 
infiltration. ~ Recent studies have demonstrated that 
Read at the Seventy-fifth Annual Meeting of The American 
Association for Thoracic Surgery, Boston, Mass., April 23-26, 
1995. 
Address for reprints: Yoshifumi Naka, MD, PhD, or David J. 
Pinsky, MD, Columbia University P&S 11-518, 630 West 
168th St., New York, NY 10032. 
Copyright © 1995 by Mosby-Year Book, Inc. 
0022-5223/95 $ .00 + 0 12/6/67831 
1434 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 11 O, Number 5 
Naka et al. 1435 
maintaining endothelial function within trans- 
planted organs is critical to successful preserva- 
tion. 26 Of the numerous factors influencing vascular 
function, nitric oxide (NO) functions as a key mod- 
ulator of normal pulmonary vascular physiology, 
mediating vasodilation, 7' s preventing neutrophil ad- 
herence to the endothelium, 9' 0 maintaining endo- 
thelial barrier properties, 1~ and inhibiting platelet 
aggregation. 3 Inasmuch as endogenous pulmonary 
NO levels plummet during the first few minutes of 
reperfusion, 4 some have suggested that inhaled NO 
may be beneficial after lung transplantation. ~2' 13 
Concerns remain, however, that inhaled NO may 
combine rapidly with superoxide generated uring 
reperfusion to form highly toxic peroxynitrite and 
hydroxyl radicals, x< 15 with potentially deleterious 
consequences for the newly reperfused pulmonary 
graft. Because NO exerts its beneficial effects on 
vascular function by stimulating soluble guanylate 
cyclase to i~acrease cyclic guanosine monophosphate 
(cGMP) in effector cells, 16 we hypothesized that 
distal stimulation of the NO/cGMP pathway at the 
level of cGMP might confer the beneficial vascular 
effects of NO without its potential toxicities. 
Methods 
Lung preservation and transplantation. Preservation 
solutions consisted of modified Euro-Collins solution 
(Baxter Healthcare Corp., Deerfield, Ill.; Na +, 10 mEq/L; 
K ÷, 115 mEq/L; C1 , 15 mEq/L; HPO4- , 85 mEq/L; 
H2PO4- , 15 mEq/L; HCO3- , 10 mEq/L; modified by 
adding 10 m! of 10% magnesium sulfate and 50 ml of 50% 
glucose solution) or Euro-Collins solution supplemented 
with the membrane-permeable nonhydrolyzable cGMP 
analog, 8-(44chlorophenylthio)-guanosine-3',5'-cGMP (8- 
pCPT-cGMP, BioLog Life Science Institute, La Jolla, 
Calif.). In inbred male Lewis rats (250 to 300 gin), the 
pulmonary artery was flushed with a 30 ml volume of 4 ° C 
preservation solution at a constant pressure of 20 mm Hg. 
The left lung was then harvested, a cuff was placed on 
each vascul~tr stump, a cylinder was inserted into the 
bronchus, and the lung was submerged for 6 hours in 4 ° C 
preservation solution. Rats matched by gender, strain, and 
size were anesthetized, intubated, and their lungs venti- 
lated with a rodent ventilator (Harvard Apparatus Co., 
South Natic k, Mass.). Orthotopic left lung transplantation 
was performed through a left thoracotomy with a rapid 
cuff technique for all anastomoses, with warm ischemic 
times maintained below 10 minutes as described previ- 
ously.4-6, 17 The bronchial crossclamp was released first to 
allow gas distribution, after which the vascular clamps 
were releaseid to reestablish blood flow. A snare was then 
passed arouind the right pulmonary artery, and Millar 
catheters (2F; Millar Instruments, Inc., Houston, Tex.) 
were introduced into the main pulmonary artery and the 
left atrium. A flow probe (Transonic, Ithaca, N.Y.) was 
placed around the main pulmonary artery. 
Experimental conditions. Three experimental condi- 
tions were tested: (1) Control: lungs were preserved in 
Euro-Collins olution alone and transplanted asdescribed 
earlier; (2) NO: lungs were preserved in Euro-Collins 
solution alone, but NO inhalation (65 ppm, monitored by 
chemiluminescence) wasbegun immediately before reper- 
fusion of the transplanted lung and continued during 
reperfusion; or (3) cGMP: 8-pCPT-cGMP (250/xmol/L) 
was added to the preservation solution. Because the 
carrier gas for NO administration was nitrogen, the gas 
mixture used for ventilation in all experiments was 70% 
oxygen and 30% nitrogen. 
Measurement of lung graft function. On-line hemody- 
namic monitoring was accomplished with MacLab soft- 
ware and a Macintosh IIci computer (Apple Computer, 
Cupertino, Calif.). Measured hemodynamic parameters 
included left atrial and pulmonary artery pressures (mil- 
limeters of mercury) and pulmonary artery flow (millili- 
ters per minute). Arterial oxygen tension (Po2, millime- 
ters of mercury) was measured uring inspiration of 70% 
oxygen and 30% nitrogen with a model ABL-2 gas ana- 
lyzer (Radiometer A/S, Copenhagen, Denmark). PVRs 
were calculated as (mean pulmonary artery pressure -
left atrial pressure)/mean pulmonary artery flow and 
expressed as millimeters of mercury per milliliter per 
minute. After baseline measurements, he native right 
pulmonary artery was ligated and serial measurements 
taken every 5 minutes until the animal was killed at 30 
minutes (or until recipient death). Hemodynamic mea- 
surements were recorded at the final time at which the 
recipient was alive. Thirty minutes after ligation of the 
native right pulmonary artery, or at the time of recipient 
death, transplanted lungs were removed, rinsed briskly in 
physiologic saline solution, and snap frozen in liquid 
nitrogen until the time of myeloperoxidase assay, per- 
formed as described. 18Previous tudies have shown 100% 
recipient survival with these techniques when lungs were 
harvested as described and immediately transplanted. 17 In 
addition, although we chose a priori to use the 30-minute 
time after transplantation to evaluate grafts to study lung 
preservation i  the immediate posttransplantation period, 
we have previously shown that well-preserved grafts can 
permit recipient survival well beyond the 30-minute ob- 
servation period. 6
Statistics. Data were evaluated by means of the Mann- 
Whitney U test or Fisher's exact est. Values are expressed 
as mean _+ standard eviation, with differences considered 
statistically signifcant ifp < 0.05. 
Results 
After 6 hours of preservation in Euro-Collins 
solution alone, grafts failed rapidly after ligation of 
the native pulmonary artery, with marked declines 
in pulmonary arterial flow and arterial oxygenation 
(Fig. 1, A and D). In sharp contrast, when 8-pCPT- 
cGMP was added to the preservation solution, he- 
modynamic (pulmonary artery flow) and functional 
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Fig. 1. Effect of inhaled NO or 8-pCPT-cGMP on pulmonary arterial flow (PA flow, ml/min, A, B and C) 
and arterial oxygenation (Po2, mm Hg, D, E, and F) after 6 hours of preservation at4 ° C in Euro-Collins 
solution, followed by lung transplantation. The native (right) pulmonary artery was ligated at time 0. A and 
D, Control: Euro-Collins olution alone (n = 6), B and E, Inhaled NO: Euro-Collins olution alone, but the 
recipient's lungs were ventilated with inhaled NO gas (65 ppm, n = 12), C and F, 8-pCPT-cGMP: 
Euro-Collins solution supplemented with the membrane-permeable nonhydrolyzable cGMP analog, 
8-(4-chlorophenylthio)-guanosine-3',5'-cGMP (250/xmol/L, n = 4). PA, Pulmonary artery. 
(arterial Po2) parameters were stabilized and recip- 
ients survived the 30-minute observation period 
(Fig. 1, C and F), whereas 8 of 12 recipients whose 
lungs were ventilated with NO gas during reperfu- 
sion showed declines in pulmonary arterial flow and 
arterial oxygenation similar to those observed in 
control animals (Fig. 1, B and E). 
When pooled data are evaluated for all animals, 
8-pCPT-cGMP added to the preservation solution 
significantly increased pulmonary artery flow (0.5 _+ 
0.3 vs 20.6 -- 2.1 ml/min, p < 0.01) (Fig. 2, A), 
decreased PVR (12.1 _+ 6.3 vs 1.1 _+ 0.2 mm Hg/ml 
per minute, p < 0.05) (Fig. 2, B), and improved 
arterial Po 2 (82.8 -+ 48 vs 369 -+ 56 mm Hg, p < 
0.05) (Fig. 2, C), compared with values in the control 
group. Inhaled NO did not show similar beneficial 
effects (PA flow, 10.6 _+ 16.0 ml/min; PVR, 6.5 _+ 5.0 
mm Hg/ml/min, Po2, 170 _+ 174 mm Hg) (Fig. 2). 
Because stimulation of the NO/cGMP pathway 
has important effects to inhibit neutrophil adher- 
ence to the reperfused coronary endothelium, and 
neutrophil infiltration has been implicated in the 
no-reflow phenomenon, we evaluated the effects of 
stimulation of this pathway on pulmonary graft 
neutrophil nfiltration. Compared with Euro-Collins 
solution alone (control group), the cGMP analog 
8-pCPT-cGMP added to the preservation solution 
was associated with a significant decline in lung 
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Fig. 2. Effects of inhaled NO or 8-pCPT-cGMP on lung preservation for transplantation. All lung 
transplants were performed after 6 hours of hypothermic preservation. Measurements were recorded at the 
fina~ time at which the recipient was alive or at 30 minutes after ligation of the native right pulmonary 
artery. A, Pulmonary arterial flow (ml/min). B, Pulmonary vascular resistance (mm Hg/ml/min). C, Arterial 
oxygenation (mm Hg) (n = 6 for control, n = 12 for inhaled NO, and n = 4 for 8-pCPT-cGMP). Means _+ 
standard eviation are shown. 
myeloperoxidase activity (3.1 _+ 0.9 vs 1.7 _+ 0.3 
AAbs 460 nm/min, respectively, p < 0.05) (Fig. 3). In 
contrast, inhaled NO gas did not alter neutrophil 
deposition (2.9 _+ 0.6 AAbs 460 nm/min, p = NS* vs 
control group) (Fig. 3). 
To determine whether the beneficial vascular 
effects of 8-pCPT-cGMP translated into improved 
recipient slurvival , we measured survival during the 
30-minute observation period after ligation of the 
native pulmonary artery. These data showed survival 
to be significantly improved by supplementation f 
the preservation solution with the cGMP analog 
compared !with controls (0% vs 100%, p < 0.005), 
but not by inhaled NO gas (33%, p = NS vs 
controls) (Fig. 4). 
Discussion 
Lung transplantation is gaining increased accep- 
tance as a therapeutic alternative for patients with 
end-stage lung disease. 19 However the lungs are 
extremely Vulnerable to ischemia-reperfusion injury, 
and current methods of preserving lungs for trans- 
* NS = Not Significant. 
plantation often do not prevent the development of
pulmonary dysfunction after transplantation. I Be- 
cause endothelium-derived NO appears to play a 
critical role in maintaining vascular homeostasis 
after reperfusion 2-6 and these levels plummet imme- 
diately on reperfusion of the transplanted lungs, 4we 
investigated whether astrategy to buttress NO levels 
at the time of reperfusion by administering NO by 
inhalation might confer beneficial vascular effects. 
There remains the theoretical concern, however, 
that the rapid interaction f exogenously administered 
NO with endogenous superoxide generated uring 
pulmonary reperfusion may liberate far more toxic 
oxygen species, such as peroxynitrite and hydroxyl 
radical. 14'1s This potentially- deleterious interaction 
has been reported in cardiac reperfusion injury, 2° 
endothelial cells, is and rat tubular hypoxia/reoxygen- 
ation injury. 21 If this interaction were to occur to a 
significant extent in vivo in the setting of lung trans- 
plantation, we hypothesized that inhaled NO might be 
deleterious during early reperfusion and that distal 
stimulation of the NO/cGMP pathway with a cGMP 
analog might confer the beneficial vascular effects of 
NO while avoiding its potential toxicities. 
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Fig. 4. Actuarial survival of the recipients (n = 6 for control, n = 12 for inhaled NO, and n = 4 for 
8-pCPT-cGMP). ***p < 0.005 vs control at 30 minutes after ligation of the native pulmonary artery (PA). 
The data presented here show that inhaled NO 
given during repeffusion had no beneficial pulmo- 
nary vascular effects compared with Euro-Collins 
solution alone. In contrast, the cGMP analog 
8-pCPT-cGMP added to the preservation solution 
resulted in reduced PVR, improved arterial oxygen- 
ation, and attenuated graft neutrophil infiltration. 
The finding that 8-pCPT-cGMP enhances pulmo- 
nary preservation is supported by the observation 
that nitroglycerin, which also stimulates guanylate 
cyclase to increase cGMP levels, is also beneficial 
after lung preservation. 5' 6 
These data are in contrast to several recent 
reports of inhaled NO given after lung transplanta- 
tion, in which inhaled NO appeared to be beneficial. 
Although one report showed that inhaled NO re- 
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duced intrapulmonary shunting, reduced PVR, and 
improved oxygenation after human lung transplan- 
tation, t3 NO was given from 12 hours to 10 days 
after transplantation, providing no assessment of the 
potential toxicities of inhaled NO during the critical 
early minutes of reperfusion. Another study, in 
which inhaled NO was given to dogs after lung 
transplantation, is difficult to assess, because pros- 
taglandin E 1 was given to all animals. 12 Prosta- 
glandin may itself attenuate neutrophil adhesion 22 
and therefore reduce the amount of superoxide 
generated by recruited neutrophils, obscuring po- 
tential toxicities related to exogenous NO admin- 
istration. For the experiments described in the 
current article, we have elected not to use prosta- 
glandin E 1 supplementation so as not to obscure the 
role of the cGMP second messenger cyclic nucle- 
otide pathway. Preliminary data of ours suggest that 
stimulation of the cyclic adenosine monophosphate 
second messenger cyclic nucleotide pathway (which 
may result from prostaglandin E 1 supplementa- 
tion e2) has overlapping effects with the cGMP path- 
way on th e pulmonary vascular milieu. 23' 24 
Inasmuch as our studies did not show a deleteri- 
ous effect of inhaled NO compared with Euro- 
Collins solution (control group), this may reflect a 
precarious balance achieved between the toxic ef- 
fects of NO and its beneficial vascular effects (vaso- 
dilation, inhibition of both neutrophil adhesion, and 
platelet aggregation). To circumvent the potential 
toxicities associated with the interaction of NO with 
superoxide, we used a membrane-permeable, non- 
hydrolyzable cGMP analog (8-pCPT-cGMP 25) to 
supplement the NO/cGMP pathway. In these exper- 
iments, addition of 8-pCPT-cGMP to the preserva- 
tion solution resulted in a marked stabilization of 
pulmonary hemodynamics after transplantation, as
well as attenuated graft neutrophil infiltration. Be- 
cause neutrophil plugging has been implicated as an 
important cause of the no-reflow phenomenon, 26'27 
attenuated neutrophil accumulation may have con- 
tributed further to the apparent reduction in PVR. 
In addition, reduced graft leukostasis may have 
reduced the toxicity of the postreperfusion vascular 
milieu, because neutrophils release reactive oxygen 
intermediates, proteases, and other toxic com- 
pounds, as tn further support of the potential thera- 
peutic utility of a cGMP analog, inhalation of the 
cGMP analog 8-bromo-cGMP has been shown to 
selectively lower PVR in a porcine mode1 of pulmo- 
nary hypertension. 29 Together, these data suggest 
that targeted elivery of a cGMP analog either by 
inhalation or by intrapulmonary instillation (as by 
pulmonary artery flushing during preservation) can 
have beneficial pulmonary vascular effects. 
Taken together, these data suggest hat stimula- 
tion of the NO/cGMP pathway at the level of cGMP, 
by supplementing the preservation solution with a 
cGMP analog, has a protective ffect on an ortho- 
topic rat left lung transplant model that is not seen 
with inhaled NO given in the immediate reperfusion 
period. These data contribute to the growing body 
of evidence indicating the important role of the graft 
vasculature in pulmonary preservation. 
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Discussion 
Dr. Steven J. Mentzer (Boston, Mass.). There is a 
tendency in the medical literature to refer to ischemia nd 
reperfusion as a single event. They are in fact two events, 
cellular hypoxia followed by reoxygenation. Many of the 
discordant findings in the field of NO and organ preser- 
vation are a result of cross-wiring these two events. An 
important aspect of the work presented by Dr. Naka is 
that it begins to differentiate the effects of cellular hypoxia 
from the injury caused by reoxygenation. I have two 
comments regarding cellular hypoxia nd the lung. First, a 
common misconception is that a hypoxic microenviron- 
ment uniformly inhibits cellular functions. We now know 
that the opposite can be true. Hypoxia can be a potent 
stimulus for both gene transcription and cellular metabo- 
lism. For example, relative hypoxia can trigger endothelial 
cells to transcribe the potent vasoconstrictors endothe- 
lin-1 and platelet-derived growth factor, or PDGF. In 
most physiologic ircumstances, such as organ preserva- 
tion, the hypoxia-induced production of vasoconstrictors 
can result in a deleterious imbalance in vasoregulators. 
By including a cGMP analog in the lung perfusate, 
these investigators have anticipated this imbalance and 
have blunted the hypoxic responses of the lung. This type 
of preemptive metabolic manipulation will doubtless play 
an increasingly important role in treatment of ischemia in 
the future. 
Second, a word of caution. Inhaled NO facilitates ven- 
tilation-perfusion matching precisely because it is inhaled. 
By definition, vasodilation induced by inhaled NO occurs 
in areas that are being ventilated. In contrast, the distal 
stimulation of the NO pathway described Dr. Naka with 
soluble mediators is independent of ventilation. Soluble 
mediators that stimulate the distal NO pathway should be 
used cautiously to avoid unanticipated ventilation-perfu- 
sion mismatching. 
Dr. Naka. Thank you for your excellent comments, Dr. 
Mentzer. We are also considering the properties of isch- 
emic endothelium. 
You mentioned about the data reported recently in 
which inhaled NO given during transplantation appeared 
to be beneficial. In the one report of human lung trans- 
plantation, inhaled NO was not given during the critical 
early minutes of reperfusion, providing no assessment of
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the potential toxicity of inhaled NO given during this 
period. In another eport of canine lung transplantation, 
prostaglandin E~, which may itself attenuate neutrophil 
infiltration and reduce superoxide generation from neu- 
trophils, was given to all animals in addition to NO, 
potentially obscuring the effects of exogenous inhaled NO. 
Dr. Shaf Keshavjee (Toronto, Ontario, Canada). Did 
your cGMP analog have any effects on the systemic 
circulation in your model. 
Dr. Naka. Although we did not evaluate the systemic 
effects of the cGMP analog in our model, all animals 
receiving the cGMP analog survived the 30-minute obser- 
vation period after transplantation, whereas all of control 
grafts failed. If an adverse ffect existed, it did not affect 
graft function or recipient survival. 
Dr. John H. Kennedy (Cambridge, England). Hypocar- 
bia apprizes vasoconstriction in cerebral vessels as some 
other systems. Did you measure carbon dioxide tension as 
you measured P02? 
Dr. Naka. We also measured carbon dioxide tensions in 
all experiments and they did not show any significant 
differences between the groups. 
